• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-K filed by Mannatech Incorporated

    4/1/26 4:45:41 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MTEX alert in real time by email
    NT 10-K 1 mtex20260331_nt10k.htm FORM NT 10-K mtex20260331_nt10k.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 12b-25

     

    NOTIFICATION OF LATE FILING

     

     

    (Check One)    

     

    ☒ Form 10-K     ☐   Form 20-F     ☐   Form 11-K     ☐   Form 10-Q

    ☐ Form 10-D     ☐   Form N-SAR     ☐   Form N-CSR

       
       

    For Period Ended: 12/31/2025

       
       

    ☐  Transition Report on Form 10-K

       

    ☐  Transition Report on Form 20-F

       

    ☐  Transition Report on Form 11-K

       

    ☐  Transition Report on Form 10-Q

       

    ☐  Transition Report on Form N-SAR

       
       

    For the Transition Period Ended:                                                                  

     

    Read Instruction (on back page) Before Preparing Form. Please Print or Type.

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: 

     

     

    PART I — REGISTRANT INFORMATION

     

    Mannatech, Incorporated

    Full Name of Registrant

     

    N/A

    Former Name if Applicable

     

    1410 Lakeside Pkwy, STE. 200

    Address of Principal Executive Office (Street and Number) 

     

    Flower Mound, TX 75028

    City, State and Zip Code

     

     

     

     

     

    PART II — RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

     

     

    (a)

     

    The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

    ☒  

    (b)

     

    The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

       

    (c)

     

    The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III — NARRATIVE

     

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    The Company is unable to file its Annual Report on Form 10‑K for the year ended December 31, 2025, within the prescribed time period without unreasonable effort or expense because our independent auditor discussed with us the possibility of a going concern issue, management needs more time to assess the repercussions and any necessary remediation efforts.  That assessment includes discussions with third-party tax advisors and review of a cost-reduction plan.

     

    The Company experienced a decline in net sales, incurred operating losses and negative cash flows from operating activities during the year ended December 31, 2025, which caused liquidity constraints.  

     

    The Company expects to file the Form 10‑K on or before the fifteenth calendar day following its prescribed due date as permitted under Rule 12b‑25.

     

    (Attach extra Sheets if Needed)

     

    PART IV — OTHER INFORMATION

     

    (1)

    Name and telephone number of person to contact in regard to this notification

     

    Yasir Haider

     

    (469)

     

    313-2749

    (Name)

     

    (Area Code)

     

    (Telephone Number)

     

    (2)

    Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).     ☒    Yes     ☐   No

     

     

     

    (3)

    Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?       ☐ Yes     ☒ No

     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

     

     

     

     

    Mannatech, Incorporated

    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date 

     

         April 1, 2026

     

    By 

     

    /s/ Landen Fredrick  

                Landen Fredrick
               

    Chief Executive Officer

     

    INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

     

       

    ATTENTION 

       
             
             

    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

     

     

     

     

     
    Get the next $MTEX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MTEX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MTEX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mannatech Announces Notification of Late Filing

    FLOWER MOUND, Texas, April 01, 2026 (GLOBE NEWSWIRE) -- Mannatech, Incorporated (NASDAQ:MTEX), ("Mannatech" or "the Company") announced today that it has filed a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange Commission with regard to its annual report on Form 10-K (the "2025 Form 10-K") for the fiscal year ended December 31, 2025. Form 12b-25 allows the Company an automatic extension of 15 additional calendar days to file the 2025 Form 10-K, which is due on March 31, 2026. The Company expects to file the 2025 Form 10-K as soon as practicable by April 15, 2026, in accordance with Rule 12b-25. The 12b-25 filing is available on the Company's website under ir

    4/1/26 6:47:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Reports Financial Results for Third Quarter 2025

    FLOWER MOUND, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2025. Third Quarter Results Net sales for the quarter ended September 30, 2025 were $29.2 million, as compared to $31.7 million for the same period in 2024, a decrease of $2.6 million, or 8.1%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $2.3 million, or 7.3%, and unfavorable foreign exchange caused a $0.2 million decrease in GAAP net sales as compared to the same period in 2024. Th

    11/12/25 4:02:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Reports Financial Results for Second Quarter 2025

    Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2025. Second Quarter Results Net sales for the quarter ended June 30, 2025 were $25.7 million, as compared to $27.7 million for the same period in 2024, a decrease of $2.1 million, or 7.4%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.8 million, or 6.5%, and unfavorable foreign exchange caused a $0.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

    8/12/25 5:18:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    $MTEX
    SEC Filings

    View All

    SEC Form NT 10-K filed by Mannatech Incorporated

    NT 10-K - MANNATECH INC (0001056358) (Filer)

    4/1/26 4:45:41 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Incorporated filed SEC Form 8-K: Leadership Update

    8-K - MANNATECH INC (0001056358) (Filer)

    3/24/26 11:36:24 AM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - MANNATECH INC (0001056358) (Filer)

    11/12/25 4:05:07 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    $MTEX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rameson Tyler bought $126,232 worth of shares (16,288 units at $7.75), increasing direct ownership by 6% to 299,197 units (SEC Form 4)

    4 - MANNATECH INC (0001056358) (Issuer)

    9/10/24 5:45:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    $MTEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jobe Larry A was granted 4,790 shares, increasing direct ownership by 8% to 62,197 units (SEC Form 4)

    4 - MANNATECH INC (0001056358) (Issuer)

    1/6/26 2:37:56 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Robbins Kevin Andrew was granted 4,790 shares, increasing direct ownership by 22% to 26,233 units (SEC Form 4)

    4 - MANNATECH INC (0001056358) (Issuer)

    1/6/26 2:36:47 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Director John Seifrick A was granted 4,790 shares, increasing direct ownership by 53% to 13,746 units (SEC Form 4)

    4 - MANNATECH INC (0001056358) (Issuer)

    1/6/26 2:35:41 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    $MTEX
    Leadership Updates

    Live Leadership Updates

    View All

    Mannatech Announces Results of Annual Shareholders' Meeting

    Mannatech, Incorporated (Nasdaq: MTEX) ("Mannatech"), a global health and wellness company committed to transforming lives to make a better world, announced that its shareholders passed all proposals put to a vote at Mannatech's annual shareholder meeting (the "Meeting") held Tuesday, June 3, 2025. Mannatech's Chairman of the Board, J. Stanley Fredrick, chaired the Meeting, and James Clavijo, Mannatech's Chief Financial Officer, spoke to the shareholders sharing the company's financial results for 2024. There were 1,900,930 outstanding shares of Mannatech's common stock as of April 8, 2025 entitled to vote and 1,478,342 shares, or approximately 77.8% represented at the Meeting, either i

    6/5/25 2:30:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Announces Appointment of Robert A. Toth as Vice Chairman of the Board of Directors

    Mannatech, Incorporated (NASDAQ: MTEX) announced that on November 20, 2024, the Board of Directors of Mannatech, Incorporated (the "Board") appointed Robert A. Toth to the Board where he will serve as Vice Chairman of the Board of Mannatech, Incorporated (the "Company") effective December 1, 2024. Mr. Toth will serve as a Class III director of the Board. Mr. Toth previously served on the Company's Board between March 2008 through May 31, 2023. Mr. Toth previously served as the Chairman of the Compensation and Stock Option Plan Committee, served on the Audit Committee, the Nominating/Governance and Compliance Committee, the Science and Marketing Committee, and from August 2014 to March 201

    11/26/24 4:30:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Announces Appointment of James Clavijo as Chief Financial Officer

    Mannatech, Incorporated (NASDAQ: MTEX) announced that the Board of Directors appointed James Clavijo as Chief Financial Officer of Mannatech Incorporated (the "Company") effective July 1, 2024. James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron (NASDAQ:LVGN), Guided Therapeutics (OTC:GTHP), Aeterna Zentaris (NASDAQ:AEZS), and Tri-source Pharma. Mr. Clavijo has led and advised companies with strategic plans for pharmaceutical commercialization and manufacturing, has negotiated licensing and drug development agreements, and he has advised c

    7/1/24 5:46:00 PM ET
    $AEZS
    $MTEX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products

    $MTEX
    Financials

    Live finance-specific insights

    View All

    Mannatech Reports Financial Results for Third Quarter 2025

    FLOWER MOUND, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2025. Third Quarter Results Net sales for the quarter ended September 30, 2025 were $29.2 million, as compared to $31.7 million for the same period in 2024, a decrease of $2.6 million, or 8.1%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $2.3 million, or 7.3%, and unfavorable foreign exchange caused a $0.2 million decrease in GAAP net sales as compared to the same period in 2024. Th

    11/12/25 4:02:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Reports Financial Results for Second Quarter 2025

    Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2025. Second Quarter Results Net sales for the quarter ended June 30, 2025 were $25.7 million, as compared to $27.7 million for the same period in 2024, a decrease of $2.1 million, or 7.4%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.8 million, or 6.5%, and unfavorable foreign exchange caused a $0.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

    8/12/25 5:18:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Reports Financial Results for First Quarter 2025

    Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its first quarter of 2025. First Quarter Highlights Net sales for the quarter ended March 31, 2025 were $26.6 million, as compared to $29.4 million for the same period in 2024, a decrease of $2.8 million, or 9.6%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.6 million, or 5.4%, and unfavorable foreign exchange caused a $1.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

    5/13/25 6:06:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    $MTEX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Mannatech Incorporated

    SC 13G - MANNATECH INC (0001056358) (Subject)

    11/1/24 11:44:29 AM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

    SC 13G/A - MANNATECH INC (0001056358) (Subject)

    1/13/23 11:03:46 AM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

    SC 13G/A - MANNATECH INC (0001056358) (Subject)

    2/7/22 6:32:28 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care